Genentech, a biotechnology corporation that operates as an independent unit within Roche Group, has reportedly announced the top-line results from its Phase III clinical trial of etrolizumab in patients with moderately to severely active ulcerative colitis.
Sources cite that studies assessing etrolizumab as an induction therapy demonstrated mixed results. HIBISCUS I induction clinical study in people without prior anti-TNF (Anti-tumor Necrosis Factor) treatment apparently met the primary endpoint.
On the other hand, the HIBISCUS II induction clinical study, which comprised patients without previous anti-TNF treatment, didn’t achieve its primary endpoint.
Studies assessing etrolizumab as a maintenance therapy